Curious how people here think the potential peptide reclassification plays out.
If some of these move back into compounding, I don’t think access really changes much. Anyone who wants peptides already has a source.
What changes is the channel.
Instead of research-grade with all the usual question marks, you’d have a legit path through a doctor and pharmacy. That alone probably shifts a decent chunk of demand.
Quality seems like the obvious win. More consistency, less guessing, fewer bad batches floating around.
Price is where I’m split.
Part of me thinks more legit supply means more competition, which should push prices down over time. But you’re also layering in consults, prescriptions, and pharmacy margins, so it may not be cheaper upfront. It could end up looking more like generic Cialis. Not dirt cheap, but more standardized and less risk.
Net, it feels like quality goes up, the grey market shrinks but doesn’t disappear, and pricing gets more predictable. Maybe it trends down longer term, but not right away.
Big question is whether this actually pulls people out of the grey market, or if most just stick with what’s already working for them.
If some of these move back into compounding, I don’t think access really changes much. Anyone who wants peptides already has a source.
What changes is the channel.
Instead of research-grade with all the usual question marks, you’d have a legit path through a doctor and pharmacy. That alone probably shifts a decent chunk of demand.
Quality seems like the obvious win. More consistency, less guessing, fewer bad batches floating around.
Price is where I’m split.
Part of me thinks more legit supply means more competition, which should push prices down over time. But you’re also layering in consults, prescriptions, and pharmacy margins, so it may not be cheaper upfront. It could end up looking more like generic Cialis. Not dirt cheap, but more standardized and less risk.
Net, it feels like quality goes up, the grey market shrinks but doesn’t disappear, and pricing gets more predictable. Maybe it trends down longer term, but not right away.
Big question is whether this actually pulls people out of the grey market, or if most just stick with what’s already working for them.









































































